The importance of dual 5⍺-reductase inhibition in the treatment of male pattern hair loss: Results of a randomized placebo-controlled study of dutasteride versus finasteride - 09/08/11
for the Dutasteride Alopecia Research Team
Durham and Research Triangle Park, North Carolina; Minneapolis, Minnesota; Dallas, Texas; and Hot Springs, Arkansas
Abstract |
Background |
Male pattern hair loss (MPHL) is a potentially reversible condition in which dihydrotestosterone is an important etiologic factor.
Objective |
Our aim was to evaluate the efficacy of the type 1 and 2 5⍺-reductase inhibitor dutasteride in men with MPHL.
Methods |
Four hundred sixteen men, 21 to 45 years old, were randomized to receive dutasteride 0.05, 0.1, 0.5 or 2.5 mg, finasteride 5 mg, or placebo daily for 24 weeks.
Results |
Dutasteride increased target area hair count versus placebo in a dose-dependent fashion and dutasteride 2.5 mg was superior to finasteride at 12 and 24 weeks. Expert panel photographic review and investigator assessment of hair growth confirmed these results. Scalp and serum dihydrotestosterone levels decreased, and testosterone levels increased, in a dose-dependent fashion with dutasteride.
Limitations |
The study was limited to 24 weeks.
Conclusion |
Dutasteride increases scalp hair growth in men with MPHL. Type 1 and type 2 5⍺-reductase may be important in the pathogenesis and treatment of MPHL.
Le texte complet de cet article est disponible en PDF.Abbreviations used : BPH, DHT, MPHL, PHL
Plan
Supported by GlaxoSmithKline. Disclosure: Drs Olsen, Hordinsky, Whiting, and Stough as well as the Dutasteride Alopecia Resarch Team all received study grant support from GSK; Drs Olsen, Hordinsky, Stough, and Whiting served as consultants to GSK during the conduct of the study; Stuart Hobbs, Melissa Ellis, Timothy Wilson, and Roger Rittmaster are employees of GSK. |
Vol 55 - N° 6
P. 1014-1023 - décembre 2006 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?